|Articles|October 16, 2020
- BioPharm International-10-15-2020
- Volume 2020 eBook
- Issue 3
Due Diligence Assessment of CMC Activities
Author(s)William J. Lambert
For planned acquisitions or licensing, careful analysis of CMC factors ensures no problem areas are overlooked.
Advertisement
Developing comprehensive chemistry, manufacturing, and controls programs are crucial to the success of a drug product. For planned acquisitions or licensing, a careful analysis of these critical factors is vital to ensure no problem areas are overlooked. Strategies for carrying out an effective due diligence exercise are described
Article Details
BioPharm International
eBook: Regulatory Sourcebook
October 2020
Pages: 42–44
Citation
When referring to this article, please cite it as W. Lambert, “Due Diligence Assessment of CMC Activities," BioPharm International Regulatory Sourcebook eBook (October 2020).
Articles in this issue
about 5 years ago
Bio/Pharma Industry Works Overtime to Find COVID-19 Therapiesabout 5 years ago
GMPs Guide COVID-19 Vaccine Manufacturingabout 5 years ago
Viral Vector API Characterization of Product-Related Impuritiesabout 5 years ago
Tackling Cybersecurity Challenges in Legacy Systemsabout 5 years ago
Strong Quality Culture: A How-To for Busy Managersabout 5 years ago
Resources, Guidelines, and Guidance Documentsabout 5 years ago
Regulatory and Standard Setting OrganizationsNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Everything to Know About Cell and Gene Therapy in 2025
2
Biologics, Obesity, China Top Financial Trends Reshaping Pharma R&D in J.P. Morgan Report
3
CGT Innovations: The Three-Pronged Strategy for Industry Growth (Part 2)
4
Overcoming Funding Challenges and Maintaining Optimism in CGTs (Part 1)
5
